Skip to main content

Piskel Kyle's Form 4/A amendment

Amended

Adaptive Biotechnologies Corp (ADPT) · filed May 20, 2025

Accession no.
0001062993-25-009904
Filed
May 20, 2025
Trade date
May 16, 2025
Filing delay
4 days
Rule 10b5-1 plan
Not checked
Original filed
May 19, 2025

This filing lists 1 non-derivative transaction. It carries over 1 transaction from the original filing that it did not restate. Open-market sales total $17.1K. It was filed 4 days after the trade.

This amendment restates part of 0001062993-25-009837 (filed May 19, 2025). The transactions it did not restate still count and are listed below.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Piskel KyleCIK 0001780662Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 16, 2025Common StockSSaleDisposed−1,929$8.89−$17,148.81269,581Direct

Carried over from the original filing

This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.

From 0001062993-25-009837 (filed May 19, 2025).

Non-derivative securities (Table I)

Non-derivative transactions carried over from 0001062993-25-009837
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 15, 2025Common StockAGrant or awardAcquired+7,815$0.00$0279,325Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

Read the full filing on SEC EDGAR (opens in a new tab)